Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
iCo-008 is a type of antibody—called a monoclonal antibody—designed to target a protein called eotaxin-1, which triggers inflammatory allergic reactions such as those found with some ocular diseases, severe asthma and inflammatory bowel disease. Monoclonal antibodies have the unique ability to bind to almost any substance, including disease organisms in the human body. Through this targeting and binding process, iCo-008 blocks eotaxin-1, neutralizing its ability to deliver the signal that triggers allergic reaction. iCo-008 is administered by intravenous injection. ICO-008: HUMAN MONOCLONAL ANTIBODY TREATING BOTH THE BACK AND FRONT OF THE EYE EDEMA POTENTIAL INDICATIONS WET AGE-RELATED MACULAR DEGENERATION (wAMD) Ocular Markets • Wet Age Related Macular Degeneration (wAMD) • Vernal & Atopic Keratoconjunctivitis • Conjunctiva Systemic Markets • • • • Inflammatory Bowel Disease, Crohn’s disease Severe Asthma (License granted to Immune Pharmaceuticals) Allergic rhinitis Atopic dermatitis PRODUCT HIGHLIGHTS • • • • Human monoclonal antibody targeting eotaxin-1 Good safety & significant clinical history: Phase 1 & 2 (n=126) iCo-008 utilizes a targeted, highly specific biological approach Eotaxin binds with high affinity to CCR3 • Afflicts the elderly • Leads to rapid vision loss • N ew literature implicates that CCR3/Eotaxin-1 axis is a target for AMD LICENSING AGREEMENTS In-licensing: Medimmune • $400,000 up-front payment • $7,000,000 milestone payments • Exclusive rights to entire body Out-licensing: Immune Pharma • $500,000 upfront received CLINICAL HISTORY • $32,000,000 incoming milestones Phase 1: (n=25) No serious adverse events • 600,000 Immune shares Phase 2: (n=101) Applied intranasally & topically to the eye • 200,000 Immune warrants • Safe and well tolerated • Evidence of efficacy in severe allergy indication: reduced post allergy nasal obstruction • 6.14% ownership with dilution provisions* RECENT & UPCOMING MILESTONES 33 License systemic rights to Immune Pharmaceuticals for US$32+ million while retaining ocular rights ❑❑ Pursuing non-dilutive funding for ocular programs • Royalties on net sales • R etained WW rights to all ocular applications * As of the date of the transaction, June 24, 2011 760-777 Hornby St. Vancouver, BC, Canada V6Z 1S4 604-602-9414 www.icotherapeutics.com